Leader in the development of permanent seed brachytherapy in the treatment of cancer.
Press Releases
NEWS RELEASE for November 24, 2008
| Contact |
Dwight Babcock 520-240-4840 dbabcock@isoray.com | Lori Woods, COO 206-604-6400 lwoods@isoray.com |
RICHLAND, Washington – IsoRay Inc. (AMEX: ISR) a medical isotope company focusing on the treatment of prostate and other malignant disease through use of its proprietary radioisotope technology, today announced that its operating subsidiary has hired Anthony G. Pasqualone as Vice President of Business Development in charge of Sales.
IsoRay Chairman and CEO Dwight Babcock said that since he was appointed, the company has been actively searching for a senior level sales manager with industry experience.
"We are fortunate to have the opportunity to hire Tony and believe he has the background and relationships to spearhead our strategy to improve sales," said Babcock.
Pasqualone has been involved in marketing brachytherapy extensively since 1989 when brachytherapy started to gain attention as a viable treatment option for prostate cancer.
He was National Sales Manager at Theragenics Corporation in 1989 where he helped develop market acceptance of Pd-103. In addition, in 1995 he brought the first stranded product to market while working with the team at Oncura (Amersham Corporation).
More recently, he was a principal and served as Vice President of Sales at SourceTech Medical which developed and introduced SeedLink to the brachytherapy market in 2003. This company was later purchased by Bard Urology, where he was a Vice President of Strategic Markets for several years.
He is an alumnus of Fordham University with a BS in Science, and is very active within support groups for men with prostate cancer. His background is in radiation oncology, where he has worked with GPO and IDN organizations, and he is recognized nationally for starting more than 400 centers in the US for prostate brachytherapy. He is married with two children and resides in Duluth, GA, where he continues to be an activist for improving quality of life for cancer patients and prostate cancer research.
Proxcelan (Cesium-131) is available at 99 medical centers and clinics across the United States and is a proprietary product of IsoRay Medical, a wholly-owned subsidiary of a public company, IsoRay, Inc. (“IsoRay”) (AMEX Symbol: ISR), based in Richland, WA.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Proxcelan Cesium-131 brachytherapy seeds, used to treat prostate and other cancers. Proxcelan seeds offer a significantly shorter half-life than the two other isotopes commonly used for brachytherapy, which results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of the longevity of common brachytherapy side effects. Proxcelan offers advantages over other isotopes used in seed brachytherapy. It delivers its therapeutic radiation faster than other isotope seeds-- Palladium-103 and Iodine-125--and at a reduced risk to patients when compared to surgery. Due to its unique characteristics, Proxcelan patients receive a higher initial dosage of radiation that attacks and kills cancer cells quickly. Its short half-life means that radiation leaves the body sooner than Iodine-125 and Palladium-103. (a) (b). IsoRay is based in Richland, Washington. More information is available about IsoRay at www.isoray.com.
(a) Armpilia CI, Dale RG, Coles IP, et al. The Determination of Radiobiologically Optimized Half-lives for Radionuclides Used in Permanent Brachytherapy Implants. Int. J. Radiation Oncology Biol. Phys. 2003; 55 (2): 378-385.
(b) Prestidge B.R., Bice W.S., Jurkovic I., et al. Cesium-131 Permanent Prostate Brachytherapy: An Initial Report. Int. J. Radiation Oncology Biol. Phys. 2005; 63 (1): 5336-5337.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Proxcelan Cesium-131 seed, whether Mr. Pasqualone will be successful in implementing IsoRay's sales strategies and whether such strategies will result in improved sales, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, and other risks detailed from time to time in IsoRay's reports filed with the SEC.